The GenFlex is a sample-to-result molecular diagnostic platform that includes sample collection, processing, amplification, and detection, the company said.
The new Series B investment was made by Northpond Ventures, with previously invested $20 million in the Australian diagnostics company.
Vienna-based Aelian combines CRISPR-Cas9 screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action.
The firm submitted its Verigene II Gastrointestinal Flex Assay to the FDA in Q4 and expects to submit Verigene II Respiratory Flex Assay to the agency in Q1 2020.
Fourth quarter revenues of $32.4 million were in line with previously reported preliminary revenues and ahead of the Wall Street estimate of $30.8 million.
The group envisions using PGDx's technology to identify effective therapy options for cancer patients and improve monitoring of patient response to therapy.
The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.
PacBio will try to take the Sequel II to the clinic in China with the help of Berry Genomics and is open to partnerships globally, including with Illumina.
News items for the week of Feb. 3, 2020.
On a conference call to discuss the firm's fiscal Q1 financial results, Twist executives detailed the firm's vision for near- and long-term growth.
The South Korean company has now received CE marking for its hepatitis B, hepatitis C, and HIV-1 detection kits, which run on its ExiStation system.
Diagnostics segment revenues for the company fell 5 percent to $38.4 million, and life sciences revenues dropped 15 percent to $12.6 million.
The company attributed its revenue shortfall to billing issues in the prenatal testing business and announced that CFO Bryan Riggsbee will be interim CEO.
The company booked a net loss of $55.6 million, or $1.69 per share, for the quarter which included litigation settlement expenses of $22.5 million.
The company announced the launch of the new products in the US and Europe as part of a product portfolio it has named Panther Scalable Solutions.
Full-year 2019 revenues grew 16 percent and the firm booked $18 million in other income from Illumina, before their acquisition deal fell apart.
The company expects that Blueprint's informatics capabilities in particular will improve variant interpretation and reporting across all its genetic test offerings.
The court dismissed BGI's counterclaim against Illumina for willful infringement of its patent but allowed the claim for induced infringement to proceed.
A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.
At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.
The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.
Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.
In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.